Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Approval for NSCLC Perioperative Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM
The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...
BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments
The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...
Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization
Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...
Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare
Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...
Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership
Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with...
Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...
Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France
French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...
J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products
A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...
China’s CDE Releases Guidelines for CGT Clinical Trials Communication
The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...
China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste
The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...
China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities
The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...
Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology
Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...
Roche Secures Diagnostics Deal with LumiraDx for $295M
Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...